一家在新西兰证券交易所（NZX）上市的公司宣布计划进口药用级MDMA用于治疗用途。
A company listed on New Zealand's stock exchange, the NZX, has announced plans to import pharmaceutical-grade MDMA for therapeutic use.
该药物在娱乐场景中被称为“莫莉”或“摇头丸”，目前正被定位用于临床环境中治疗创伤后应激障碍（PTSD）。
The drug, known recreationally as "molly" or "ecstasy," is being positioned for use in clinical settings to treat post-traumatic stress disorder.
该公司正定位于一个小但正在增长的国际领域，该领域涉及供应医用级迷幻化合物的企业。
A company listed on New Zealand's stock exchange has announced plans to import pharmaceutical-grade MDMA for use in treating post-traumatic stress disorder, positioning the firm within a small but growing international field of businesses supplying medical-grade psychedelic compounds.
在治疗环境中，MDMA在医疗监督下与结构化心理治疗一起使用，这种方法在多个国家引起了研究兴趣，作为对传统疗法无效的PTSD患者的潜在治疗手段。
The drug is better known outside clinical settings by its recreational names, "molly" and "ecstasy." In therapeutic contexts, MDMA is administered under medical supervision alongside structured psychotherapy sessions, an approach that has drawn research interest in several countries as a potential treatment for patients who have not responded to conventional PTSD therapies.
医用MDMA的进口和配发仍受严格监管，反映其在未获批准的临床使用之外仍被列为受控物质。
Regulatory pathways for importing and dispensing the substance for medical use remain tightly controlled, reflecting its continued classification as a controlled drug outside approved clinical use.
该公告使一家新西兰上市公司加入了仍处于早期阶段的迷幻医学领域，该领域吸引了投资者的密切关注，因为多个司法管辖区正在重新考虑对具有治疗潜力物质的限制。
The announcement adds a New Zealand-listed company to a still-nascent psychedelic-medicine sector that investors have watched closely as several jurisdictions reconsider restrictions on substances with therapeutic potential.
此类项目的商业规模通常取决于当地卫生监管机构批准供应和处方安排的速度。
The commercial scale of any such venture will typically depend on how quickly local health regulators approve supply and prescribing arrangements.